Reid Huber Sold $167,507 Worth of Incyte (INCY) Stock; Randgold Resources Limited (GOLD) Covered By 10 Bullish Analysts Last Week

February 23, 2018 - By Louis Casey

Reid Huber who is presently the EVP – Chief Scientific Officer of Incyte Corp recently unloaded 1,958 shares of the corporation. The insider trade has $167,507 U.S. Dollars total value, at an average stock price per share of $85.6. The regulatory filing shows that Reid Huber now has rights to about 0.02% of the Delaware-based company’s market cap A report documented published February 22, 2018 with the Washington-based Security and Exchange Commission, disclosed here, shows the complete information of the transaction.

Among 16 analysts covering Randgold-Resources (NASDAQ:GOLD), 10 have Buy rating, 0 Sell and 6 Hold. Therefore 63% are positive. Randgold-Resources had 33 analyst reports since July 24, 2015 according to SRatingsIntel. JP Morgan maintained Randgold Resources Limited (NASDAQ:GOLD) on Thursday, April 7 with “Neutral” rating. RBC Capital Markets upgraded Randgold Resources Limited (NASDAQ:GOLD) on Monday, August 24 to “Outperform” rating. The stock of Randgold Resources Limited (NASDAQ:GOLD) earned “Overweight” rating by Morgan Stanley on Thursday, December 1. The firm earned “Neutral” rating on Monday, August 15 by JP Morgan. The firm has “Overweight” rating by JP Morgan given on Monday, November 7. The stock has “Hold” rating by Deutsche Bank on Tuesday, February 9. The firm earned “Buy” rating on Friday, January 13 by Berenberg. The stock of Randgold Resources Limited (NASDAQ:GOLD) earned “Buy” rating by Goldman Sachs on Monday, June 27. HSBC downgraded the stock to “Hold” rating in Tuesday, February 9 report. On Monday, October 26 the stock rating was downgraded by HSBC to “Hold”. See Randgold Resources Limited (NASDAQ:GOLD) latest ratings:

12/02/2018 Broker: JP Morgan Old Rating: Overweight New Rating: Overweight Old Target: $103 New Target: $101 Maintain
05/02/2018 Broker: Scotia Capital Rating: Hold New Target: $101.0 Maintain

Investors sentiment increased to 1.04 in 2017 Q3. Its up 0.02, from 1.02 in 2017Q2. It improved, as 39 investors sold Incyte Corporation shares while 161 reduced holdings. 59 funds opened positions while 149 raised stakes. 188.97 million shares or 2.28% more from 184.77 million shares in 2017Q2 were reported. Asset Management accumulated 0.06% or 16,232 shares. Spark Inv Ltd Liability Com reported 0.34% in Incyte Corporation (NASDAQ:INCY). Huntington Bankshares holds 0% or 8 shares in its portfolio. State Of Alaska Department Of Revenue reported 0.05% of its portfolio in Incyte Corporation (NASDAQ:INCY). Torray Limited Liability accumulated 144,412 shares or 1.67% of the stock. Sanctuary Wealth Advsrs Limited Liability Co reported 8,944 shares. Vanguard Grp Inc reported 17.39 million shares. Meeder Asset Mngmt Inc invested in 0.04% or 3,398 shares. Millennium Mngmt Lc, New York-based fund reported 341,732 shares. Los Angeles Capital Mgmt & Equity Rech has 22,816 shares. Bancorp Of Montreal Can invested 0.01% of its portfolio in Incyte Corporation (NASDAQ:INCY). Moreover, Ing Groep Nv has 0.01% invested in Incyte Corporation (NASDAQ:INCY). The Texas-based Employees Retirement System Of Texas has invested 0.01% in Incyte Corporation (NASDAQ:INCY). Scout Invs holds 92,011 shares. 100 were accumulated by Winfield Associates.

Among 24 analysts covering Incyte (NASDAQ:INCY), 20 have Buy rating, 0 Sell and 4 Hold. Therefore 83% are positive. Incyte has $18000 highest and $85 lowest target. $127.89’s average target is 50.12% above currents $85.19 stock price. Incyte had 78 analyst reports since August 6, 2015 according to SRatingsIntel. The stock of Incyte Corporation (NASDAQ:INCY) has “Buy” rating given on Monday, September 11 by BMO Capital Markets. On Friday, February 12 the stock rating was maintained by Brean Capital with “Buy”. The company was initiated on Tuesday, January 5 by Raymond James. The company was maintained on Wednesday, August 5 by UBS. As per Wednesday, November 1, the company rating was maintained by BMO Capital Markets. The stock of Incyte Corporation (NASDAQ:INCY) earned “Buy” rating by Goldman Sachs on Wednesday, November 18. The rating was maintained by BMO Capital Markets on Thursday, October 12 with “Buy”. RBC Capital Markets initiated Incyte Corporation (NASDAQ:INCY) on Wednesday, July 13 with “Outperform” rating. BMO Capital Markets maintained Incyte Corporation (NASDAQ:INCY) on Friday, July 21 with “Buy” rating. As per Tuesday, August 18, the company rating was maintained by Argus Research.

The stock increased 0.57% or $0.48 during the last trading session, reaching $85.19. About 1.32 million shares traded. Incyte Corporation (NASDAQ:INCY) has risen 72.84% since February 23, 2017 and is uptrending. It has outperformed by 56.14% the S&P500.

Since August 29, 2017, it had 1 buying transaction, and 8 insider sales for $124,780 activity. Another trade for 2,111 shares valued at $263,875 was made by Stein Steven H on Tuesday, August 29. 1,958 Incyte Corporation (NASDAQ:INCY) shares with value of $167,507 were sold by Huber Reid M. Trower Paul sold $415,230 worth of Incyte Corporation (NASDAQ:INCY) on Tuesday, September 5. On Thursday, August 31 the insider SWAIN PAULA J sold $2.80 million. 70,502 Incyte Corporation (NASDAQ:INCY) shares with value of $8.42 million were sold by Hoppenot Herve. Siegel Eric H. sold $250,068 worth of stock. 6,760 shares valued at $668,361 were sold by GRYSKA DAVID W on Friday, January 5.

Analysts await Incyte Corporation (NASDAQ:INCY) to report earnings on May, 3. They expect $-0.05 EPS, up 94.79% or $0.91 from last year’s $-0.96 per share. After $0.02 actual EPS reported by Incyte Corporation for the previous quarter, Wall Street now forecasts -350.00% negative EPS growth.

Incyte Corporation focuses on the discovery, development, and commercialization of proprietary therapeutics in oncology in the United States and internationally. The company has market cap of $18.03 billion. It offers JAKAFI for the treatment of myelofibrosis and polycythemia vera cancers. It currently has negative earnings. The company??s clinical stage products include ruxolitinib cream that is in Phase II clinical trial for the treatment of alopecia areata and atopic dermatitis; and baricitinib, which is in Phase III clinical trial for treatment of rheumatoid arthritis.

The stock decreased 0.44% or $0.38 during the last trading session, reaching $85.24. About 362,604 shares traded. Randgold Resources Limited (NASDAQ:GOLD) has risen 7.63% since February 23, 2017 and is uptrending. It has underperformed by 9.07% the S&P500.

Randgold Resources Limited explores for and develops gold deposits in Sub-Saharan Africa. The company has market cap of $8.01 billion. It holds interests in the Morila gold mine, the Loulo gold mine, and the Gounkoto gold mine, which are located in Mali, West Africa; Tongon mine situated within the Nielle exploitation permit in the north of Côte d’Ivoire; and Kibali mine located in the Democratic Republic of Congo. It has a 29.19 P/E ratio. The firm was founded in 1995 and is based in St.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: